目的 观察索拉非尼治疗晚期肾癌的疗效和安全性.方法 22例晚期转移性肾透明细胞癌患者给予单药口服索拉非尼治疗9～23个月,每8周评定疗效,并登记、处理不良反应.结果 部分缓解(PR)1例、疾病稳定(SD)15例、疾病进展(PD)4例、死亡2例,无完全缓解(CR)病例.主要不良反应有手足综合征、胃肠道反应及血压升高等.结论 索拉非尼能够稳定病情,延长晚期RCC患者无进展生存时间,且毒副反应轻,耐受性好.%Objective To investigate the efficacy and adverse effects of Sorafenib in the treatment of metastatic RCC. Methods Twenty - two patients with MRCC were administered with Sorafenib and the treatment ranged from 9 to 23 months. The efficacy was evaluated every eight weeks. Adverse effects were registered and treated. Results One patient attained PR, 15 patients achieved SD, 4 patients had progressive disease, 2 patients died. CR has not been observed in our group. The major adverse effects were hand- foot syndrome, gastrointestinal reaction and hypertension. Conclusion Sorafenib can stabilize disease and extend the progression - free survival with MRCC, and its toxicity was obviously minor compared with that of other traditional chemotherapy.
展开▼
